Posted: June 23, 2016 Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and...
Raje N, Faber E, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser C, Cronier DM, Wooldridge JE, Anderson...READ MORE
Posted: June 23, 2016 Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in...
Herrero AB, García-Gómez A, Garayoa M, Corchete LA, Hernández JM, San Miguel J, Gutierrez NC. Am J Pathol. 2016 Jun 11. pii: S0002-9440(16)30113-4. doi:...READ MORE
Posted: June 23, 2016 CD38 levels are associated with response and complement inhibitors contribute...
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T,...READ MORE
Posted: June 23, 2016 The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell...
Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P. J Immunol. 2016 Jun 17. pii: 1501351. [Epub ahead of...READ MORE
Posted: June 23, 2016 Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone...
Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil...READ MORE
Posted: June 20, 2016 Exclusive Q&A with Dr. Hearn Jay Cho, Mt. Sinai Hospital, NY, NY
A promising avenue of clinical research in multiple myeloma is the use of immune checkpoint inhibitors. As most myeloma patients know, there is a constant...READ MORE
Posted: June 20, 2016 MMRF Holds CoMMpass Collaborator Meetings at ASCO 2016
On Saturday June 4 at ASCO, the MMRF Research Team met with our CoMMpass trial collaborators to discuss the current status of the trial and new directions for...READ MORE
Posted: June 13, 2016 MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) FOUNDER KATHY GIUSTI TO CO-CHAIR...
The Multiple Myeloma Research Foundation (MMRF), a leader in precision medicine, today announced that its founder, Kathy Giusti, whom Fortune recently named as...READ MORE
Posted: June 9, 2016 ASCO Educational Session: Consolidation and Maintenance: Moving Beyond...
The learning objectives for this session included: 1. Describing optimal approaches and evidence-based data outlining the role of consolidation therapy after...READ MORE
Posted: June 7, 2016 Day Three Wrap-Up: ASCO 2016
Last year daratumumab (Darzalex) received accelerated approval by the U.S. Food and Drug Administration to treat myeloma patients that had at least three prior...READ MORE